Surfactant
Phase 3Small molecule
Surfactant is one of 56 small molecule programs targeting Adult Acute Respiratory Distress Syndrome. It is currently in Phase 3.
4
Indications
14
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
57 competitors in Lung Transplantation
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Opsumit
Johnson & JohnsonApproved
Rapamune
PPrism Pharmaceuticals
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tavalisse
RRigel Pharmaceuticals
Approved
Imuran
LLegacy Health System
Approved
Rezurock
KKadmon, a Sanofi Company
Approved
Calcineurin Inhibitors
SanofiApproved
Cecon
MMcGuff Pharmaceuticals, Inc.
Approved
Afinitor
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infants1 trial
Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS
Unknown status·—·Phase 2·NCT01723683·60 enrolled
Respiratory Distress Syndrome1 trial
7 more indications
Newborn Respiratory Distress Syndrome1 trial
Altitude1 trial
Pulmonary Surfactant(PS) Therapy at High Altitude Area
Completed·—··NCT03440333·400 enrolled
Neonatal respiratory distress1 trial
Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study
Unknown status·—··NCT03479450·200 enrolled
Adult Acute Respiratory Distress Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Surfactant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNICHD Neonatal Research Network